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Introduction
Human African trypanosomiasis (HAT), or sleeping sickness, is
endemic in sub-Saharan Africa, claiming the lives of about
30000 people every year and putting approximately 60 million
people at risk of infection.
[1] HAT is a progressive and fatal dis-
ease caused by the protozoan parasites Trypanosoma brucei
gambiense and T. b. rhodesiense, which are transmitted to the
human host by the bite of the tsetse fly. If left untreated the
disease progresses to the central nervous system and is ulti-
mately fatal. There is a clinical need for more effective drug
therapies. Current therapies are toxic and have inappropriate
treatment regimens for a rural African setting. There are also
problems with treatment failures.
[1–3]
Differences in metabolic pathways have been discovered be-
tween parasite and host, which may be exploited for drug dis-
covery programmes. An example of such a difference is found
in thiol metabolism and the response of T. brucei to oxidative
stress.
[4–8] Studies have shown that trypanosomatid parasites
are uniquely dependent on trypanothione (N
1,N
8-bis(glutathio-
nyl)spermidine) as their principal thiol, in contrast to most
other organisms (including their mammalian hosts) that use
glutathione (g-l-glutamyl-l-cysteinylglycine, GSH).
[9] In T. brucei
trypanothione is synthesised from GSH and spermidine (Spd)
by an ATP-dependent C N ligase, trypanothione synthetase
(TryS; EC 6.3.1.9), with N
1- and N
8-glutathionylspermidine as in-
termediates.
[10,11]
Selective inhibition of the trypanothione pathway with
chemical agents (targeting trypanothione reductase, trypare-
doxin, and tryparedoxin peroxidise) or classical gene knockout
studies have shown a clear trypanocidal effect.
[12,13] TbTryS has
also been genetically validated as a drug target, with RNAi and
gene knockout studies confirming that TbTryS is essential for
T. brucei growth in both bloodstream and procyclic forms, and
that there is no alternative bypass mechanism available to the
parasite.
[14,15]
Before commencing a drug discovery programme, TbTryS
was assessed for its suitability as a drug target using the traffic
light scoring system that we have developed in house.
[16] The
assessment indicated TbTryS is an attractive target for drug de-
velopment, especially as it is unlikely to have resistance or tox-
icity issues, as there is no obvious bypass metabolism or equiv-
alent enzyme in humans.
[10] The main concern was the poten-
tial druggability of the target. Because the active site of TbTryS
is large enough to accommodate trypanothione and precur-
sors, this may be an issue if the active site is a large featureless
pocket, as is observed in T. brucei trypanothione reductase
(TbTryR).
[17] However, the structure of TryS from Leishmania
major suggests this is not the case,
[18] and the potential to co-
crystallise ligands with the protein to inform a chemistry pro-
gramme was a distinct advantage. Importantly, TbTryS is a bi-
functional enzyme, which catalyzes the biosynthesis and hy-
drolysis of the GSH–Spd adduct trypanothione. The two cata-
lytic domains are separate in Leishmania. The N-terminal
domain is a cysteine-containing amidohydrolase/peptidase
amidase site, with the C-terminal ATP grasp domain responsi-
ble for the synthetase activity of the enzyme.
[18]
Figure 1 shows the only previously disclosed inhibitor of
TbTryS, compound 1.
[19] Whilst a valuable tool molecule, the
optimisation and development of this phosphinate inhibitor
into a potential clinical candidate is limited due to the peptidic
nature of such a compound, with a high polar surface area
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for cellular penetration, metabolic stability, bioavailability, and
blood–brain barrier permeability).
Herein we describe a medicinal chemistry programme to de-
velop inhibitors of TbTryS, which gave rise to some potent
compounds. We recently reported the biological experiments
to chemically validate TbTryS using five of these compounds:
9, 20, 71, 84, and 89.
[15,20]
Results and Discussions
High-throughput screening
As previously described, a high-throughput screening assay for
TbTryS was developed and validated.
[20] TbTryS was then
screened against a 62000 compound diversity set at single-
point concentration (30 mm). This gave rise to >720 hits (com-
pounds with TbTryS percentage inhibition >33% at 30 mm).
These hits were clustered and filtered down to 174 com-
pounds that underwent potency testing (10-point, half-log di-
lution dose–response curves from which an accurate IC50 could
be calculated). This gave rise to the six putative hit series, plus
a number of singletons. Appropriate hits were then re-pur-
chased to confirm identity and activity. A round of purchasing
(where available) and synthesis of analogues was initiated to
validate the series and to investigate the SAR around these po-
tential hit series to assess optimisation towards lead series.
Table 1 shows the hit series identified from the HTS screen,
and the ligand efficiencies of compounds from these series.
[21]
Although there are six distinct chemical series shown in
Table 1, the series can be clustered into two distinct groups
that share common pharmacophoric features. Attempts were
made to co-crystallise hit ligands in the protein to obtain an X-
ray crystal structure showing ligands in the binding domain,
but unfortunately these have been unsuccessful so far.
Initial hit exploration around series/group 1
Group 1 series were identified as having a common pharmaco-
phore with two hydrogen bond acceptors (HBA) in 1,5 relation-
ship, with one of the HBAs from a heterocyclic ring. The phar-
macophore also includes regions of hydrophobicity, indicating
a potential lipophilic pocket.
Hit series 1a: thiazole methylene sulfone
The synthetic route to prepare this series involved the conden-
sation of a thioamide with an appropriate a-bromoketone
(Table 2), based on the methodology of Dunn et al.
[22] The cor-
responding a-bromoketones could be bought or synthesised
from the corresponding acetyl compound (see Experimental
Section below for more details). Activities of hit series 1acom-
pounds against TbTryS are listed in Table 2.
Exploration around the scaffold of 1a(Table 2) shows that 2-
substitution with a small substituent, methyl (compound 4)
and fluorine (compound 5), is tolerated without loss of poten-
cy. An electron-donating substituent at the 3-position, as in
Figure 1. Previously published TbTryS inhibitor: compound 1, Ki
app: 500–
1200 nm.
Table 1. Hit series clusters identified from HTS.
Series Structure LE
[a]
1a 0.44
1b 0.45
1c 0.33
2a 0.33
2b 0.30
2c 0.29
[a] Ligand efficiency, calculated as  0.6 ln(IC50)/(heavy atom count).
[21]
Table 2. SAR around hit series 1a.
Compd R IC50 [mm]
[b] Compd R IC50 [mm]
[b]
3 H 1.2 9 3-F 0.4
4 2-CH3 3.2 10 4-CH3 >100
5 2-F 1.1 11 4-CF3 >100
6 3-OCH3 12.0 12 3,4-di-Cl 2.5
7 3-CF3 1.1 13 3,4-di-F 0.4
8 3-Cl 0.4
[a] Yields: 60–87%; the synthesis of compound 9 was previously de-
scribed by Torrie et al.
[20] [b] IC50 values against TbTryS.
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stituted compound 3; however, all potency was regained if the
3-position group was changed to an electron-withdrawing
group, such as trifluoromethyl (compound 7). In addition, a
slight improvement in potency was observed for the 3-F (9)
and 3-Cl (8) derivatives (IC50: 0.4 mm). These analogues showed
sub-micromolar potency is achievable within this hit series.
Substitution at the 4-position was not tolerated with either an
electron-withdrawing or -donating group. Both methyl (10)
and trifluoromethyl (11) were found to be inactive. However,
3,4-disubstitution with an electron-withdrawing substituent at
the 3-position restored potency (compounds 12 and 13), al-
though ligand efficiency was decreased.
Hit series 1b: tetrazole methylene carbonyl
In this series, the thiazole subunit is replaced by a tetrazole,
and the sulfone by a carbonyl group. The tetrazoles were alky-
lated with a-bromoketones (Table 3). Amide analogue 23 was
synthesised via an amide coupling of the corresponding acid,
which in turn was obtained from saponification of the ethyl
ester.
Subtle trends in SAR similar to series 1a were observed in
series 1b(Table 3). In particular, there was a 25-fold gain in po-
tency for the 3,5-dichloro analogue 20, relative to the unsub-
stituted scaffold 14. This could be due to the greater lipophilic-
ity of this compound causing an increase in nonspecific bind-
ing, although the ligand efficiency improved (LE from 0.39 to
0.45), suggesting a favourable specific interaction. It was possi-
ble to modify the ketone moiety to an amide without loss of
potency (compare amide 23 (IC50=0.6 mm), with ketone 20
(IC50=0.3 mm)). In going from methyl (21) to ethyl (22)t otert-
butyl ketone (20), an improvement in potency was observed
(IC50: 8.8 to 6.5 to 0.3 mm, respectively), indicating lipophilic
bulk in this area is required. In contrast, the phenyl ketone 24
shows a marked loss in potency, with an IC50 value of 45 mm.
Hit series 1c: tetrahydroindazole methylene amide
The pyrazole core for series 1c was made by condensation of
ethyl hydrazinoacetate with the commercially available dione.
The ester was then hydrolysed, allowing amide couplings
using standard methodology (Table 4).
[23,24]
Small changes to optimise the amide group in this series
generated a “flat” SAR plateau (25–28; Table 4). Aliphatic
amides (29–31) were tolerated, albeit at weaker potency, but
bulky rigid substitution with the phenyl 32 and cyclohexyl 33
moieties was not tolerated, with complete loss in potency ob-
served. Tertiary amide 34 with two bulky benzyl groups also
lost all potency, but the less bulky diethyl amide 35 retained
some inhibitory activity.
Initial hit exploration around series/group 2
Following the HTS campaign we also identified three hit series
based around a second pharmacophore. This second group of
hit series described a slightly different pharmacophore, with
the heteroatom of the heterocycle in a 1,6 relationship with
the HBA motif of the sulfonamide. These hit series had higher
molecular weight and generally lower potency, with lower
ligand efficiency (see Table 1). To explore the SAR around these
series, compounds were purchased and screened. Data for
these are listed in Tables 5, 6, and 7.
None of the group 2 series offered any benefits in terms of
potency over the compound series from group 1. In addition,
the DMPK data indicated less favourable properties of group 2
Table 3. SAR around hit series 1b.
Compd R R
1 TbTryS IC50 [mm]
14 H tBu 8.8
15 4-CF3 tBu >100
16 3-Cl, 4-CH3 tBu 7.2
17 3-F tBu 1.5
18 3-CF3 tBu 3.5
19 3,5-di-F tBu 1.9
20 3,5-di-Cl tBu 0.3
21 3,5-di-Cl CH3 6.5
22 3,5-di-Cl CH2CH3 2.7
23 3,5-di-Cl N(CH3)2 0.6
24 3,5-di-F Ph 45
[a] Conditions: NaI, K2CO3, DMF, 908C; yields: 44–86%; the synthesis of
compound 20 was previously described by Torrie et al.
[20]
Table 4. SAR around hit series 1c.
Compd R
1 R TbTryS IC50 [mm]
25 H( +/ )-CH(CH3)Ph 5.6
26 HC H 2-4-chlorophenyl 3.0
27 HC H 2-2-thiophene 3.9
28 HC H 2CH2Ph 5.6
29 H( +/ )-CH(CH3)CH2CH3 12
30 HC H 2CH2CH3 13
31 HC H 2CH2OCH3 30
32 HP h >100
33 H cHex >100
34 CH2Ph CH2Ph >100
35 CH2CH3 CH2CH3 15
[a] Conditions: 1) ethyl 2-hydrazinylacetate, Et3N, EtOH, reflux, 61% yield;
2) 2m NaOH, THF/H2O (2:1), 89% yield; 3) RR
1NH, EDC·HCl, HOBt, DIPEA,
DMF, 508C; yields: 79–80%.
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group 1 (see Table 12 below). Therefore, further optimisation
work was focussed on the group 1 series.
Hit to lead optimisation strategy
Hit series 1a–c were successfully validated and shared an over-
lapping pharmacophore for TbTryS activity (Figure 2), demon-
strating clear SAR and a visible potential for further optimisa-
tion. The pharmacophoric features of the three group 1 series
scaffolds were hybridised into one new core scaffold, which
was based on an indazole (Figure 3). One of the indazole nitro-
gen atoms becomes the HBA, and
the other is used for attachment of
the other HBA. This indazole series
is also predicted to have reasona-
ble physicochemical properties:
low molecular weight, clogP<5,
and low PSA. For example, com-
pound 60 (Table 8) has Mr=
292 Da, clogP=4.0, and PSA=
35  
2.
Validation of the indazole series
The indazole scaffold was prepared as shown in Scheme 1. In-
dazole was first iodinated (at the 3-position) using standard
conditions.
[25] A Suzuki reaction afforded the 3-aryl intermedi-
ate. Alkylation of the N1 nitrogen atom with the required a-
chloroketone (or arylmethylchloride) gave final products 60,
71, and 75–79. Alternatively for compounds 61–70, the alkyla-
tion of the 3-iodoindazole was completed first and the Suzuki
reaction, to add the aryl substituent, was employed as a final
step.
3-Indazole substitution
Table 8 shows the data for key compounds from the initial SAR
study, describing changes to the aromatic group at position 3
Table 5. SAR around hit series 2a.
Compd R TbTryS IC50 [mm]
36 2-thiophene 8.5
37 5-(2,4-dimethylthiazole) 2.2
38 4-(1,3,5-trimethylpyrazole) 2.6
39 1-naphthyl >100
40 2,5-dimethoxyphenyl >100
41 3-(2,5-dimethylthiophene) 24
42 tBu 37
Table 6. SAR around hit series 2b.
Compd R
2 R
1 R TbTryS IC50 [mm]
43 HH H >50
44 H 2-CH3 H1 5
45 H 2-Cl H 25
46 H H 2,5-di-Cl 16
47 H H 4-NHCOCH3 5.9
48 H H 4-OCH3 11
49 H 2-CH3 4-OCH3 4.0
50 H 2-CH3 4-NHCOCH3 1.7
51 H 2-Cl 4-NHCOCH3 3.7
52 CH3 H 4-NHCOCH3 >50
Table 7. SAR around hit series 2c.
Compd R R
1 TbTryS IC50 [mm]
53 H 2,5-difluorophenyl 6.1
54 H phenyl-4-COCH3 8.7
55 H 2,5-dichlorophenyl 6.3
56 H 3,4-dichlorophenyl 5.8
57 H 2-naphthyl 2.4
58 Ph 4-methylphenyl >100
Table 8. SAR around lead series 3.
Compd R R
1 TbTryS IC50 [mm]L E
[a]
59 Ph OCH3 20 0.32
60 Ph tBu 0.15 0.43
61 4-chlorophenyl tBu >100
62 4-indole tBu 3.7 0.30
63 4-(N-methyl)indole tBu >100
64 2-naphthyl tBu >100
65 4-pyridyl tBu 0.3 0.41
66 2-furanyl tBu 1.9 0.38
67 3-pyridyl tBu 3.0 0.35
68 3-thiophenyl tBu 0.4 0.42
69 4-(N-isobutyl)pyrazole tBu >100
70 3-chlorophenyl tBu 0.35 0.39
71
[b] 3-fluorophenyl tBu 0.09 0.42
[a] Ligand efficiency, calculated as  0.6 ln(IC50)/(heavy atom count).
[21]
[b] Compound 71 reported previously.
[20]
Figure 3. Generation of the new scaffold.
Figure 2. Group 1 common
pharmacophore: R and R
1 are
hydrophobic binding do-
mains; N and O (boxed) are
the hydrogen bond acceptor
motifs (1,5 relationship); X, Y,
and Z are C, N, O, or S; Q is C
or SO (sulfone).
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pound 60 (R=phenyl), had an IC50 value of 150 nm in the
TbTryS enzyme assay (LE calculated as 0.43) and was the most
potent compound to date. Para substituents led to loss in ac-
tivity (e.g. 61, 63, 64, and 69). This is possible evidence for the
presence of a tight binding pocket into which the aromatic
subunit sits. A variety of heterocycles were tolerated, although
some gave a 10-fold loss in activity, such as the 2-furanyl com-
pound 66 and 3-pyridyl compound 67. The 3-fluorophenyl
motif (71,I C 50=90 nm,L E =0.42) was more potent than 3-
chlorophenyl (70,I C 50=354 nm), and was used as the standard
template for exploration of substituent SAR around the R
1 po-
sition (see Tables 9–11 below).
Having established the indazole as a potent heterocyclic
core with good ligand efficiency, a number of SAR studies
were carried out to explore chemical optimisation around this
scaffold.
Investigation of alternative HBA moieties
We were concerned that the ketone group could react with
nucleophiles, so a number of alternative HBAs were investigat-
ed. The initial sulfone analogue 74 (TbTryS IC50=120 nm)w a s
found to be equipotent to the ketone 60 (Table 9). The posi-
tion from which the pendant HBA is attached to the core scaf-
fold was also investigated. In compounds 72 and 73 the sul-
fone HBA is appended from the 3-position of the indazole core
(Table 9). This modification had little effect on activity, which is
probably due to the symmetry of the molecule. For ease of
synthesis, further HBA modifications were investigated at the
N1 position of the indazole.
Approaches were made to use a heterocycle as the second
HBA motif (Table 10). Pyridine and oxazole were investigated,
but showed lower activity than the ketone or sulfone groups.
Amide HBA analogues
Alkylation of the 3-arylindazole (synthesis shown in Scheme 2)
with ethylbromoacetate, followed by saponification, yielded
the indazole-N-acetic acid intermediate. This was coupled
under standard amide coupling conditions to the appropriate
amine to give access to amide analogues.
Encouragingly, the ketone subunit could be replaced by a
simple amide without loss of potency or ligand efficiency
(Table 11). Thus the diethyl and dimethyl amides (87 and 88)
had IC50 values similar to that of the ketone 71, with com-
pound 88 having a ligand efficiency of 0.44. Potency was re-
tained when fusing the dialkyl amide into an N-piperidine
amide (89 TbTryS IC50=135 nm), but activity was completely
abolished with a larger alkyl aromatic substituent (e.g. 86
IC50>100 mm).
Addition of an appended basic amine, to potentially pick up
the TbTryS endogenous substrate Spd binding domain interac-
tions and improve ligand potency, was investigated. This basic
group could also improve the aqueous solubility of our com-
pounds and lower the lipophilicity (logP). Although the pipera-
Scheme 1. General synthesis of indazole analogues. Conditions: 1) KOH, I2,
DMF, as in Edwards et al.,
[25] 89% yield; 2) ArB(OH)2,N a 2CO3, DME, EtOH,
H2O, yields: 50–78%; 3) NaH, DMF, a-haloketone (or other), yields: 37–62%.
Synthesis of compounds 71 and 89 were described previously.
[20]
Table 9. SAR around indazole sulfone analogues.
Compd R TbTryS IC50 [mm]L E
[a]
72 H 0.22 0.40
73 4-fluoro 0.08 0.41
74 – 0.12 0.40
[a] Ligand efficiency, calculated as  0.6 ln(IC50)/(heavy atom count).
[21]
Table 10. SAR around pendant heterocyclic side chain indazoles.
Compd R TbTryS IC50 [mm]L E
[a]
74 SO2tBu 0.12 0.40
75 2-pyridyl 2.9 0.33
76 3-pyridyl 4.5 0.32
77 2,5-dimethyl-4-oxazole 28 0.26
78 5-phenyl-3-isoxazole >100
79 5-methyl-3-isoxazole >100
[a] Ligand efficiency, calculated as  0.6 ln(IC50)/(heavy atom count).
[21]
Scheme 2. Synthesis of amide analogues. Conditions: 1) NaH, DMF, ethyl
bromoacetate, as in Fujimura et al.,
[29] yields: 37–62%; 2) NaOH, THF/H2O,
95% yield; 3) HOBt, EDC, DMF, DIPEA, R1R2NH; yields: 40–48%.
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relative to 71), and were less efficient binders (ligand efficien-
cies of 0.29 and 0.28 respectively), they were still sub-micromo-
lar inhibitors of the TbTryS enzyme, with TbTryS IC50 values of
0.86 and 0.83 mm, respectively. If the second basic amine
centre was removed and the compounds were truncated to
make the C2- and C3-linked dimethyl amine compounds 83
and 84, a significant improvement in potency (six- and 18-fold,
respectively) over the analogous piperazines was observed.
These compounds were also significantly more efficient bind-
ers than compounds 80 and 90, with respective ligand efficien-
cies of 0.38 and 0.39. The C3-linked dimethylamine compound
84 was observed to be the most potent compound to date,
with a TbTryS IC50 value of 45 nm. Compound 84 shows im-
proved physicochemical properties over compound 60, espe-
cially in decreased lipophilicity, with a clogP value of 2.8
(1.3 units lower than that of 60), and Mr=354 Da and PSA=
50  
2.
As compound 84 shows similar potency to an analogue not
containing an appended amine (71,I C 50 90 nm) it is unlikely
that compound 84 has picked up the Spd binding domain.
This conclusion is supported by competition binding studies
which revealed that the com-
pounds displayed mixed inhibi-
tion with respect to Spd, and
did not show classical competi-
tive binding kinetics.
[20] Finally,
capping the NH group of the
amide of 84 with a methyl
group (compound 85) resulted
in a fourfold decrease in poten-
cy, and the C3-linked imidazole
81 was eightfold less potent
than the dimethylamine.
Cell potency and DMPK param-
eters for key compounds
Following the discovery of
promising novel TryS inhibitors,
compounds were progressed
into a trypanosomal cell prolifer-
ation assay and a human cell
counter-screen. Selected com-
pounds were also screened in an
in vitro metabolic clearance
assay (Table 12), to assess suita-
bility for series progression. Met-
abolic stability studies using
pooled human liver microsomes
indicate a range of stabilities.
Compounds from the group 2
series are highly metabolically
unstable. However, compounds
8, 26, and 71 are reasonably
metabolically stable, suggesting
nothing fundamentally problem-
atic with these scaffolds in terms
of cytochrome P450-driven metabolism.
Table 12 also shows cell data for key compounds from sever-
al of the various series of TbTryS inhibitors discovered. Al-
though these compounds were not toxic to the MRC5 mam-
malian cell line, there was up to a 100-fold decrease in going
from enzyme to trypanosomal cell efficacy, even with the lead
compounds 71 and 84 (TbTryS IC50: 90 and 45 nm, respective-
ly). While these cell potencies are equivalent to the drugs eflor-
nithine (22 mm) and nifurtimox (2 mm) currently in clinical use
for late-stage human African trypanosomiasis, they are much
less potent than the alternative arsenic-containing drug melar-
soprol (8 nm), although arsenic-based compounds do show
significant toxicity in the clinic.
[26]
As this large potency shift between the enzyme IC50 values
and parasite EC50 values was unexpected, further experiments
were carried out to confirm whether hit compounds were en-
tering the cell and acting on-target. As described fully else-
where, exposing T. brucei parasites to the model TbTryS inhibi-
tors 89 and 84 (2 EC50 for 72 h) resulted in trypanothione
levels dropping to <10% of wild-type levels.
[15,20] In addition,
there was a corresponding increase in the TbTryS substrate
Table 11. Amide side chain indazoles.
Compd R
1 R
2 TbTryS IC50 [mm]L E
[a]
80 (CH2)3-N-methylpiperazine H 0.83 0.28
81 (CH2)3-N1-imidazole H 0.35 0.32
82 (CH2)2-N-Boc-piperazine H 2.9 0.22
83 (CH2)2N(CH3)2 H 0.145 0.38
84
[b] (CH2)3N(CH3)2 H 0.045 0.39
85 (CH2)3N(CH3)2 CH3 0.17 0.35
86 CH2-4-chlorophenyl H >100
87 CH2CH3 CH2CH3 0.20 0.39
88 CH3 CH3 0.11 0.44
89
[b] fused into piperidine ring 0.14 0.38
90 (CH2)2-N-methylpiperazine H 0.86 0.29
[a] Ligand efficiency, calculated as  0.6 ln(IC50)/(heavy atom count).
[21] [b] Compounds 84 and 89 reported
previously.
[15,20]
Table 12. Trypanosome cell, human (MRC5) cell, and pooled human microsomal intrinsic clearance (Cli) data
for key (representative) compounds from series 1–3.
Compd Series TbTryS IC50 [mm] Tb EC50 [mm] MRC5 EC50 [mm] Cli [mLmin
 1g
 1]
81 a 0.41 22 >50 0.9
26 1c 14 14 >50 3.0
36 2a 8.5 32 >50 9.1
57 2c 2.4 19 >50 17
71 3 0.09 7.9 >50 1.6
84 3 0.045 5.4 20 ND
[a]
89 3 0.14 5.1 >50 ND
[a]
[a] Not determined.
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acting on-target.
As previously reported, the on-target effects of these hit
compounds were further confirmed by generating TbTryS
single knockout (SKO) and TbTryS overexpressing (OE) cell
lines. Western blot analysis and densitometry demonstrated
that TbTryS protein levels were decreased in the SKO cells and
elevated in the OE cell line, relative to wild-type cells, and
these cell lines showed the expected changes in potency to 89
(EC50 values: 20.4, 6.9, and 44.5 mm for wild-type, SKO, and OE
cell lines, respectively) and 84 (EC50 values: 7.1, 1.2, and
23.3 mm for wild-type, SKO, and OE cell lines, respectively), con-
firming that TbTryS is the specific target of these com-
pounds.
[15,20]
Conclusions
In this work we successfully took HTS hits, clustered them into
putative hit series, and rationalised their activities based on
common pharmacophores. Initial investigation of SAR around
the hit series confirmed an overlapping pharmacophore, and
the optimisation potential of group 1 hit series in particular.
Following the SAR on group 1 series, a hybridisation strategy
and scaffold-hopping approach led us to discover the indazole
lead series. Optimisation of this series for potency and im-
proved DMPK properties led to compounds 71 and 84, which
displayed in vitro enzyme potencies >10-fold improved over
the best HTS hits. Attempts so far to co-crystallise our inhibi-
tors with the TbTryS enzyme have failed to produce robust
data.
Although these indazoles inhibit TbTryS with IC50 values of
<100 nm, they failed to show sub-micromolar potency in a try-
panosome proliferation assay. This can be rationalised by the
observation that parasites can survive with low levels of trypa-
nothione beyond the timeframe of the standard whole-para-
site proliferation assay. The extension of the time-course in
screening assay format is prohibited by the need for repeated
dilutions of samples to remain in log-phase growth, leading to
unacceptable variability. The lead compounds do, however,
show a robust biochemical effect in T. brucei, and are proven
to act on-target, inhibiting TbTryS in cells.
[15,20] The current lead
compounds could also prove very useful in combination thera-
py with known trypanocides (such as melarsoprol), as studies
have revealed TryS-depleted T. brucei procyclics are significant-
ly more susceptible to trypanocides.
[27] Our compounds are the
most advanced, potent, and drug-like (as predicted by physico-
chemical and in vitro DMPK properties) inhibitors of TbTryS re-
ported to date, and are extremely useful leads to further ex-
plore the trypanothione pathway in kinetoplastids.
Experimental section
Chemistry
1H NMR spectra were recorded on either Bruker Avance DPX 500
or Bruker Avance 300 spectrometers. Chemical shifts (d) are ex-
pressed in ppm. Signal splitting patterns are described as singlet
(s), broad singlet (bs), doublet (d), triplet (t), quartet (q), multiplet
(m) or combination thereof. LC–MS analyses were performed with
either an Agilent HPLC 1100 series instrument connected to a
Bruker Daltonics MicrOTOF, or an Agilent Technologies 1200 series
HPLC connected to an Agilent Technologies 6130 quadrupole LC–
MS; both instruments were connected to an Agilent diode-array
detector. LC–MS chromatographic separations were conducted
with a Phenomenex Gemini C18 column, 50 3.0 mm, 5 mm particle
size; mobile phase, H2O/CH3CN +0.1% HCOOH 80:20!5:95 over
3.5 min, and then held for 1.5 min; flow rate: 0.5 mLmin
 1. High-
resolution electrospray MS measurements were performed on a
Bruker Daltonics MicrOTOF mass spectrometer. Thin-layer chroma-
tography (TLC) was carried out on Merck silica gel 60 F254 plates
using UV light and/or KMnO4 for visualisation. TLC data are given
as the Rf value with the corresponding eluent system specified in
brackets. Column chromatography was performed using RediSep 
4 or 12 g silica pre-packed columns. LCMS chromatographic sepa-
rations were conducted with a Waters Xbridge C18 column, 50 mm
  2.1 mm, 3.5 mm particle size; Method A: mobile phase, H2O/
CH3CN + 0.1% NH3; linear gradient 80:20!5:95 over 3.5 min, and
then held for 1.5 min; flow rate 0.5 mLmin
 1. All reactions were
carried out under dry and inert conditions, unless otherwise stated.
Compounds in series 1a:
2-(tert-Butylsulfonylmethyl)-4-(3-fluorophenyl)thiazole (9): Syn-
thesis previously described.
[20] To a stirred solution of 3-fluoroaceto-
phenone (250 mg, 1.81 mmol) in THF (6 mL), was added trimethyl-
phenylammonium tribromide (681 mg, 1.81 mmol) solution in THF
(4 mL). The reaction was stirred at room temperature for 18 h; the
resulting white precipitate was filtered off, and the filtrate was
added to petroleum ether (PE; 20 mL). The PE solution containing
the product was washed with H2O (30 mL) and then dried (MgSO4).
The solvent was then removed in vacuo to give intermediate 2-
bromo-1-(3-fluorophenyl)ethanone (390 mg, 99%) as a pale-
yellow oil; [M+H]
+=217/219. To a stirred solution of 2-bromo-1-
(3-fluorophenyl)ethanone (326 mg, 1.8 mmol) in EtOH (20 mL) was
added 2-(tert-butylsulfonyl)ethanethioamide (386 mg, 1.98 mmol),
and the reaction was heated at reflux and stirred for 2 h. The sol-
vent was then removed in vacuo to give a crude residue which
was purified by column chromatography (CH2Cl2!10% MeOH/
CH2Cl2 eluent) to give the title compound 9 (380 mg, 81%) as a
white solid:
1H NMR ([D6]DMSO, 500 MHz): d=8.40 (1H, bs), 8.31
(2H, m), 7.70 (2H, m), 5.15 (2H, bs), 1.4 (9H, bs); [M+H]
+ =314;
HRMS C14H16FNO2S2 calcd: 314.0679, obsd: 314.0690.
Compounds 3–8 were prepared according to the same procedures
as described above for the preparation of compound 9, using the
corresponding acetophenone.
2-((tert-Butylsulfonyl)methyl)-4-(phenyl)thiazole (3):
1H NMR
([D6]DMSO, 500 MHz): d=8.23 (1H, s), 7.98 (2H, dd, J=1.4, 8.5 Hz),
7.46 (2H, t, J=7.5 Hz), 7.37 (1H, t, J=12.5 Hz), 5.07 (2H, bs),
1.39 ppm (9H, bs); [M+H]
+ =296; HRMS C14H17NO2S2 calcd:
296.0767, obsd: 296.0773.
2-((tert-Butylsulfonyl)methyl)-4-(2-methylphenyl)thiazole (4):
1H NMR ([D6]DMSO, 500 MHz): d=7.88 (1H, m), 7.59 (1H, m), 7.31
(3H, m), 5.06 (2H, bs), 2.42 (3H, s), 1.38 ppm (3H, s); [M+H]
+ =
310; HRMS C15H19NO2S2 calcd: 310.0930, obsd: 310.0943.
2-((tert-Butylsulfonyl)methyl)-4-(2-fluorophenyl)thiazole (5):
1H NMR ([D6]DMSO, 500 MHz): d=8.10 (2H, m), 7.44 (1H, m), 7.35
(2H, m), 5.10 (2H, m), 1.39 ppm (9H, s); [M+H]
+ =314; HRMS
C14H16FNO2S2 calcd: 314.0679, obsd: 314.0690.
ChemMedChem 2012, 7, 95–106   2012 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chemmedchem.org 101
Trypanothione Synthetase Inhibitors2-((tert-Butylsulfonyl)methyl)-4-(3-methoxyphenyl)thiazole (6):
1H NMR ([D6]DMSO, 500 MHz): d=8.26 (1H, s), 7.55 (1H, m), 7.52
(1H, m), 7.38 (1H, t, J=8 Hz), 6.95 (1H, m), 5.08 (2H, s), 3.82 (3H,
s), 1.39 ppm (9H, s); [M+H]
+ =326; HRMS C15H19NO3S2 calcd:
326.0879, obsd: 326.0888.
2-(tert-Butylsulfonylmethyl)-4-(3-trifluoromethylphenyl)thiazole
(7):
1H NMR ([D6]DMSO, 500 MHz): d=8.49 (1H, bs), 8.30 (2H, m),
7.74 (2H, m), 5.12 (2H, bs), 1.4 ppm (9H, bs); [M+H]
+=364; HRMS
C15H16F3NO2S2 calcd: 364.0647, obsd: 364.0639.
2-((tert-Butylsulfonyl)methyl)-4-(3-chlorophenyl)thiazole (8):
1H NMR ([D6]DMSO, 500 MHz): d=8.38 (1H, bs), 8.03 (1H, m), 7.95
(1H, m), 7.51 (1H, m), 7.44 (1H, m), 5.09 (2H, bs), 1.39 (9H, s);
13C NMR (125 MHz, CDCl3): d=23.8, 52.3, 61.6, 116.9, 124.4, 126.6,
128.4, 130.1, 134.9, 135.6, 154.0, 156.9 ppm; [M+H]
+ =330/332;
HRMS C14H16ClNO2S2 calcd: 330.0384, obsd: 330.0384.
Compounds 9–13 were obtained from Maybridge.
Compounds in series 1b:
1-(5-(3,5-Dichlorophenyl)-2H-tetrazol-2-yl)-3,3-dimethylbutan-2-
one (20): Synthesis previously described.
[20] A mixture of commer-
cially available 5-(3,5-dichlorophenyl)tetrazole (0.215 g, 1.0 mmol),
1-bromopinacolone (0.14 mL, 1.0 mmol) and diisopropylethylamine
(0.19 mL, 1.1 mmol) in CH3CN (5 mL) was heated at 758C for
3 days. The mixture was cooled, diluted with EtOAc (15 mL), and
filtered through a plug of silica. The filtrate was concentrated and
purified by chromatography on silica (eluent: EtOAc/hexane 0!
50%) to give the title compound 20 (0.270 g, 86%) as a white
solid:
1H NMR (CDCl3, 300 K): d=8.08 (2H, d, J=1.9 Hz), 7.48 (1H, t,
J=1.9 Hz), 5.71 (2H, s), 1.36 ppm (9H, s);
13C NMR (125 MHz,
CDCl3): d=26.2, 43.7, 56.6, 125.3, 130.0, 130.3, 135.7, 163.4,
204.2 ppm; [M+H]
+ =313; HRMS C13H14Cl2N4O calcd: 313.0586,
obsd: 313.0601.
2-(5-(3,5-Dichlorophenyl)-2H-tetrazol-2-yl)-N,N-dimethylaceta-
mide (23): A mixture of 5-(3,5-dichlorophenyl)tetrazole (0.215 g,
1.0 mmol), NaI (0.150 g, 1.0 mmol) and K2CO3 (0.210 g, 1.5 mmol) in
DMF (5 mL) was heated at 908C until effervescence was nearly
complete. 2-Chloro-N,N-dimethylacetamide (0.11 mL, 1.1 mmol)
was added, and the mixture was heated at 908C overnight. The
mixture was diluted with H2O (15 mL) and allowed to stand for sev-
eral hours. The precipitate was collected by filtration and washed
with H2O and Et2O to give the title compound 23 (0.150 g, 50%) as
a white solid:
1H NMR (CDCl3, 300 K): d=8.09 (2H, d, J=1.9 Hz),
7.47 (1H, t, J=1.9 Hz), 5.58 (2H, s), 3.17 (3H, s), 3.07 ppm (3H, s);
[M+H]
+ =300; HRMS C11H11Cl2N5O calcd: 300.0413, obsd:
300.0411.
Compounds below were prepared according to the same proce-
dures as described above for the preparation of compound 23,
using the corresponding aryl tetrazole and a-haloketone.
3,3-Dimethyl-1-(5-phenyl-2H-tetrazol-2-yl)butan-2-one (14):
1H NMR (CDCl3, 300 K): d=8.17 (2H, m), 7.51 (3H, m), 5.70 (2H, s),
1.35 ppm (9H, s); [M+H]
+ =245; HRMS C13H16N4O calcd: 245.1397,
obsd: 245.1387.
1-(5-(3-Fluorophenyl)-2H-tetrazol-2-yl)-3,3-dimethylbutan-2-one
(17):
1H NMR (CDCl3, 300 K): d=7.98 (1H, d, J=7.7 Hz), 7.88 (1H, d,
J=9.3 Hz), 7.48 (1H, m), 7.19 (1H, td, J=8.3 and 2.1 Hz), 5.71 (2H,
s), 1.32 ppm (9H, s); [M+H]
+ =263; HRMS C13H15FN4O calcd:
263.1303, obsd: 263.1291.
1-(5-(3,5-Difluorophenyl)-2H-tetrazol-2-yl)-3,3-dimethylbutan-2-
one (19):
1H NMR (CDCl3, 300 K): d=7.72 (2H, m), 6.94 (1H, tt, J=
8.8 and 2.4 Hz), 5.71 (2H, s), 1.36 ppm (9H, s); [M+H]
+=281;
HRMS C13H14F2N4O calcd: 281.1208, obsd: 281.1210.
1-(5-(3,5-Dichlorophenyl)-2H-tetrazol-2-yl)propan-2-one (21):
1H NMR (CDCl3, 300 K): d=8.08 (2H, d, 1.9 Hz), 7.48 (1H, t, 1.9 Hz),
5.51 (2H, s), 2.30 ppm (3H, s); [M+H]
+ =271/273; HRMS
C10H8Cl2N4O calcd: 271.0148, obsd: 271.0141.
1-(5-(3,5-Dichlorophenyl)-2H-tetrazol-2-yl)butan-2-one (22):
1H NMR (CDCl3, 300 K): d=8.09 (2H, d, 1.9 Hz), 7.50 (1H, t, 1.9 Hz),
5.52 (2H, s), 2.57 (2H, q, J=7.2 Hz), 1.19 ppm (3H, t, J=7.2 Hz);
[M+H]
+ =285/287; HRMS C11H10Cl2N4O calcd: 285.0304, obsd:
285.0292.
2-(5-(3,5-Difluorophenyl)-2H-tetrazol-2-yl)-1-phenylethanone
(24):
1H NMR (CDCl3, 300 K): d=8.02 (2H, m), 7.72 (3H, m), 7.58
(2H, t, J=7.8 Hz), 6.93 (1H, tt, J=8.8 and 2.4 Hz), 6.16 ppm (2H, s);
[M+H]
+ =301; HRMS C11H6F2N4O calcd: 301.0895, obsd: 301.0901.
Compounds 15, 16 and 18 were obtained from Maybridge.
Compounds in series 1c:
N-(4-Chlorobenzyl)-2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-
indazol-1-yl)acetamide (26): To a stirred suspension of 2-(trifluor-
oacetyl)cyclohexanone (1 g, 5.151 mmol) and ethylhydrazinoace-
tate hydrochloride (2.39 g, 15.5 mmol) in EtOH (30 mL) was added
Et3N (2.17 mL, 15.5 mmol) and the reaction heated at reflux for
24 h. The reaction mixture was cooled to room temperature and
the solvent removed in vacuo. The resultant crude residue was
taken up in CH2Cl2, washed (H2O, brine), dried (MgSO4) and con-
centrated in vacuo. The resultant crude residue was purified by
column chromatography, eluting with 0–50% EtOAc/hexane, to
give ethyl 2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)a-
cetate (864 mg, 61%) as a white solid; [M+H]
+ =277.
To a stirred solution of ethyl 2-(3-(trifluoromethyl)-4,5,6,7-tetrahy-
dro-1H-indazol-1-yl)acetate (691 mg, 2.5 mmol) in 1:1 THF/H2O
(30 mL) was added 2m (aq) NaOH (5 mL, 10 mmol), and the reac-
tion stirred for 3 h. The solvent was then removed in vacuo to give
a crude residue which was suspended in H2O, acidified (1m aq.
HCl), stirred for 5 min, filtered and the precipitate dried in vacuo to
give 2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic
acid (550 mg, 89%) as a white solid; [M+H]
+ =249.
To a stirred solution of 2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-
indazol-1-yl)acetic acid (124 mg, 0.5 mmol), 4-chlorobenzylamine
(0.061 mL, 0.5 mmol) and 1-hydroxybenzotriazole hydrate (68 mg,
0.5 mmol) in N,N-dimethylformamide (DMF; 3 mL) at 508C was
added N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochlo-
ride (96 mg, 0.5 mmol) and N,N’-diisopropylethylamine (0.18 mL,
1 mmol) and the reaction stirred for 16 h. The reaction mixture was
cooled to room temperature, taken up in EtOAc, washed (H2O,
brine), dried (MgSO4) and concentrated in vacuo. The resultant
crude residue was purified by reversed-phase HPLC (method A), to
give title compound 26 (120 mg, 79%) as a white solid:
1H NMR
([D6]DMSO, 500 MHz): d=8.78 (1H, t, J=5.9 Hz), 7.41 (2H, m), 7.30
(2H, m), 4.84 (2H, s), 4.30 (2H, d, J=3.0 Hz), 2.56 (2H, m), 2.51 (2H,
m), 1.74 (2H, m), 1.67 ppm (2H, m);
13C NMR (125 MHz, CDCl3): d=
19.9, 21.2, 21.9, 22.2, 42.8, 52.3, 116.1, 120.6, 122.7, 128.8, 128.9,
133.5, 136.0, 140.1, 166.3 ppm; [M+H]
+ =372; HRMS
C17H17ClF3N3O calcd: 372.1085, obsd: 372.1103.
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1-yl)acetamide (35): By proceeding in a similar manner to com-
pound 26, using 2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-inda-
zol-1-yl)acetic acid and diethylamine the title compound 35
(100 mg, 80%) was obtained as a white solid.
1H NMR ([D6]DMSO,
500 MHz): d=5.10 (2H, s), 3.37 (2H, q, J=7.2, 7.5 Hz), 3.27 (2H, q,
J=7.1 Hz), 1.71 (4H, m), 1.17 (3H, t, J=7.1 Hz), 1.03 ppm (3H, t,
J=7.1 Hz); [M+H]
+ =304; HRMS C14H20F3N3O calcd: 304.1631,
obsd: 304.1628.
Compounds 25, 27, 28, 31, 32, 33 and 34 were obtained from
Asinex. Compounds 29 and 30 were obtained from ChemDiv.
Compounds in series 2a:
2-Methyl-N-((5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl)pro-
pane-2-sulfonamide (42): tert-Butylsulfinyl chloride (0.18 mL,
1.5 mmol) was added to a solution of (5-methyl-2-phenyl-2H-1,2,3-
triazol-4-yl)methanamine (0.188 g, 1.0 mmol) and Et3N (1.4 mL,
10 mmol) in CH2Cl2 (10 mL) at 08C. The mixture was stirred at 08C
for 2 h and then quenched with aqueous NaHCO3. The phases
were separated and the aqueous phase was extracted with CH2Cl2.
The combined organic phases were dried (Na2SO4) and concentrat-
ed. Chromatography on silica (50–100% EtOAc/PE 40:60) gave 2-
methyl-N-((5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl)propane-
2-sulfinamide as an orange solid (0.240 g, 82%):
1H NMR (CDCl3,
300 K): d=8.01 (2H, d, J=8.4 Hz), 7.47 (2H, t, J=7.9 Hz), 7.33 (1H,
t, J=7.3 Hz), 4.50 (1H, dd, J=14.1 and 4.7 Hz), 4.36 (1H, dd, J=
14.1 and 7.5 Hz), 3.60 (1H, m), 2.42 (3H, s), 1.27 ppm (9H, s); [M+
H]
+=293.
A solution of 2-methyl-N-((5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)-
methyl)propane-2-sulfinamide (0.146 g, 0.5 mmol) in CH2Cl2
(7.5 mL) was treated with mCPBA (Aldrich,  77%; 0.225 g,
 1.0 mmol) and stirred at room temperature for 45 min. The reac-
tion was quenched with 2m aqueous NaHSO3 (10 mL) and saturat-
ed aqueous NaHCO3 (10 mL). The organic phase was applied to a
plug of silica and eluted with CH2Cl2/EtOAc (0!100%) to give title
compound 42 as a white solid (0.107 g, 69%):
1H NMR (CDCl3,
300 K): d=8.01 (2H, m), 7.49 (2H, m), 7.34 (1H, tt, J=7.4 and
1.1 Hz), 4.51 (2H, d, J=5.7 Hz), 4.43 (1H, m), 2.44 (3H, s), 1.47 ppm
(9H, s); [M+H]
+=309; HRMS C14H20N4O2S calcd: 309.1307, obsd:
309.1312.
Compounds in series 2a, 2b and 2c:
Compounds 36–41 were obtained from Maybridge. Compounds
43, 44, 45, 53, and 54 were obtained from ChemDiv. Compound
46 was obtained from ChemBridge. Compounds 47–52 were ob-
tained from Asinex. Compounds 55–57 were obtained from Life
Chemicals. Compound 58 was obtained from Enamine.
Compounds in series 3:
1-(3-(3-Fluorophenyl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one
(71): The synthesis was previously described elsewhere.
[20]
3-Iodo-1H-indazole was prepared as reported by Edwards et al;
[25]
[M+H]
+ =245.
A capped process vial containing 3-iodo-1H-indazole (366 mg,
1.5 mmol), 3-fluorophenylboronic acid (252 mg, 1.8 mmol), 2m (aq)
Na2CO3 (1.12 mL, 2.25 mmol) and tetrakis-(triphenylphosphine)pal-
ladium(0) in 7:3:2 DME/H2O/EtOH (3 mL) was degassed, flooded
with argon and irradiated (Biotage Initiator) at 1508C for 20 min. 3-
Fluorophenylboronic acid (126 mg, 0.9 mmol) and 2m (aq) Na2CO3
(0.56 mL, 1.12 mmol) were added, the system degassed, flooded
with argon and irradiated (Biotage Initiator) at 1508C for 20 min.
The reaction mixture was taken up in EtOAc, washed (H2O, 1m (aq)
NaOH, brine), dried (MgSO4) and concentrated in vacuo. The resul-
tant crude residue was purified by column chromatography, elut-
ing with 0–50% EtOAc/hexane, to give 3-(3-fluorophenyl)-1H-inda-
zole (196 mg, 62%) as a white solid.
To a stirred suspension of 60% NaH (72 mg, 1.79 mmol) in DMF
(4 mL) was added 3-(3-fluorophenyl)-1H-indazole (95 mg,
0.448 mmol) and the reaction stirred for 10 min. To the reaction
mixture 1-bromopinacolone (0.24 mL, 1.79 mmol) was added, the
reaction heated at 758C and stirring continued for 66 h. The reac-
tion mixture was cooled to room temperature, diluted with EtOAc,
washed (H2O, brine), dried (MgSO4) and concentrated in vacuo. The
crude residue was purified by column chromatography, eluting
with 0–50% EtOAc/hexane to give title compound 71 (80 mg,
58%) was obtained as a white solid:
1H NMR ([D6]DMSO,
500 MHz): d=8.12 (1H, d, J=4.1 Hz), 7.84 (1H, m), 7.71 (1H, m),
7.59 (1H, m), 7.55 (1H, m), 7.45 (1H, m), 7.27 (2H, m), 5.75 (2H, s),
1.38 ppm (9H, s); [M+H]
+=311; HRMS C19H19FN2O calcd:
311.1554, obsd: 311.1555.
By proceeding in a similar manner to compound 71, using 3-(3-flu-
orophenyl)-1H-indazole (or 3-phenyl-1H-indazole) and the corre-
sponding alkylating agent, the following compounds were ob-
tained.
1-(3-Phenyl-1H-indazol-1-yl)-3,3-dimethylbutan-2-one (60):
1H NMR ([D6]DMSO, 500 MHz): d=8.09 (1H, d, J=8.2 Hz), 7.97 (2H,
m), 7.54 (3H, m), 7.43 (2H, m), 7.25 (1H, m), 5.73 (2H, s), 1.28 ppm
(9H, s);
13C NMR (125 MHz, CDCl3): d=26.4, 43.5, 53.4, 109.0, 121.2,
121.6, 122.1, 126.7, 127.6, 128.0, 128.8, 133.5, 141.8, 144.9,
207.9 ppm; [M+H]
+ =293; HRMS C19H20N2O calcd: 293.1648, obsd:
293.1658.
3-(3-Fluorophenyl)-1-(pyridin-2-ylmethyl)-1H-indazole (75):
1H NMR ([D6]DMSO, 500 MHz): d=8.63 (1H, d, J=4.5 Hz), 8.06 (1H,
d, J=8.5 Hz), 7.83 (1H, m), 7.75 (1H, m), 7.58 (1H, m), 7.47 (2H, m),
7.42 (1H, m), 7.27 (1H, m), 7.21 (1H, m), 7.12 (1H, m), 6.95 (1H, d,
J=8.0 Hz), 5.83 ppm (2H, s); [M+H]
+ =304; HRMS C19H14FN3
calcd: 304.1245, obsd: 304.1258.
3-(3-Fluorophenyl)-1-(pyridin-3-ylmethyl)-1H-indazole (76):
1H NMR ([D6]DMSO, 500 MHz): d=8.63 (1H, d, J=2.0 Hz), 8.49 (1H
dd, J=1.5, 5.0 Hz), 8.13 (1H, d, J=8.5 Hz), 7.87 (2H, t, J=8.5 Hz),
7.72 (1H, dt, J=2.0, 9.5 Hz), 7.69 (1H, dt, J=2.0, 9.5 Hz), 7.58 (1H,
m), 7.50 (1H, m), 7.35 (1H, dd, J=4.5, 8.0 Hz), 7.28 (2H, m),
5.81 ppm (2H, s); [M+H]
+ =304; HRMS C19H14FN3 calcd: 304.1245,
obsd: 304.1235.
4-((3-(3-Fluorophenyl)-1H-indazol-1-yl)methyl)-2,5-dimethyloxa-
zole (77):
1H NMR ([D6]DMSO, 500 MHz): d=8.10 (1H, d, J=
8.5 Hz), 7.83 (1H, m), 7.77 (1H, m), 7.71 (1H, m), 7.58 (1H, m), 7.48
(1H, m), 7.27 (2H, m), 5.52 (2H, bs), 3.35 (3H, bs), 2.36 ppm (3H,
bs); [M+H]
+ =322; HRMS C19H16FN3O calcd: 322.1350, obsd:
322.1345.
3-((3-(3-Fluorophenyl)-1H-indazol-1-yl)methyl)-5-phenylisoxazole
(78):
1H NMR ([D6]DMSO, 500 MHz): d=8.15 (1H, d, J=8.0 Hz),
7.86 (4H, m), 7.77 (1H, m), 7.59 (1H, m), 7.51 (5H, m), 7.30 (2H, m),
6.95 ppm (2H, s); [M+H]
+ =370; HRMS C23H16FN3O calcd:
370.1350, obsd: 370.1345.
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(79):
1H NMR ([D6]DMSO, 500 MHz): d=8.13 (1H, d, J=8.50), 7.86
(1H, m), 7.80 (1H, m), 7.74 (1H, m), 7.59 (1H, m), 7.51 (1H, m), 7.28
(2H, m), 6.08 (1H, s), 5.80 (2H, s), 2.32 ppm (3H, s); [M+H]
+ =308;
HRMS C18H14FN3O calcd: 308.1194, obsd: 308.1179.
By proceeding in a similar manner to compound 71, using the cor-
responding boronic acid and 1-(3-iodo-1H-indazol-1-yl)-3,3-dime-
thylbutan-2-one, the following compounds were obtained:
1-(3-(4-Chlorophenyl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one
(61):
1H NMR ([D6]DMSO, 500 MHz): d=8.09 (1H, d, J=8.3 Hz),
8.00 (2H, m), 7.59 (2H, m), 7.55 (1H, d, J=8.5 Hz), 7.45 (1H, m),
7.27 (1H, m), 5.74 (2H, s), 1.28 ppm (9H, s); [M+H]
+ =327/329;
HRMS C19H19ClN2O calcd: 327.1259, obsd: 327.1265.
1-(3-(1H-Indol-4-yl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one
(62):
1H NMR ([D6]DMSO, 500 MHz): d=11.21 (1H, s), 8.00 (1H, d,
J=8.2 Hz), 7.55 (2H, m), 7.44 (3H, m), 7.24 (2H, m), 6.88 (1H, m),
5.75 (2H, s), 1.30 ppm (9H, s); [M+H]
+ =332; HRMS C21H21N3O
calcd: 332.1757, obsd: 332.1754.
3,3-Dimethyl-1-(3-(1-methyl-1H-indol-4-yl)-1H-indazol-1-yl)bu-
tan-2-one (63):
1H NMR ([D6]DMSO, 500 MHz): d=8.01 (1H, d, J=
8.4 Hz), 7.57 (3H, m), 7.43 (1H, t, J=7.5 Hz), 7.39 (1H, d, J=3.2 Hz),
7.33 (1H, t, J=7.8 Hz), 7.23 (1H, t, J=7.5 Hz), 6.87 (1H, d, J=
3.0 Hz), 5.75 (2H, s), 3.86 (3H, s), 1.30 ppm (9H, s); [M+H]
+ =346;
HRMS C22H23N3O calcd: 346.1914, obsd: 346.1913.
3,3-Dimethyl-1-(3-(naphthalen-2-yl)-1H-indazol-1-yl)butan-2-one
(64):
1H NMR ([D6]DMSO, 500 MHz): d=8.56 (1H, s), 8.30 (1H, d,
J=8.4 Hz), 8.14 (2H, m), 8.06 (1H, d, J=8.6 Hz), 7.97 (1H, d,
7.7 Hz), 7.57 (3H, m), 7.47 (1H, m), 7.31 (1H, t, J=7.5 Hz), 5.78 (2H,
s), 1.29 ppm (9H, s); [M+H]
+ =343; HRMS C23H22N2O calcd:
343.1805, obsd: 343.1806.
3,3-Dimethyl-1-(3-(pyridin-4-yl)-1H-indazol-1-yl)butan-2-one (65):
1H NMR ([D6]DMSO, 500 MHz): d=8.69 (2H, dd, J=1.6, 6.1 Hz),
8.22 (1H, d, J=8.3 Hz), 7.97 (2H, dd, J=1.6, 6.2 Hz), 7.59 (1H, d,
J=8.5 Hz), 7.48 (1H, t, J=7.5 Hz), 7.32 (1H, t, J=7.5 Hz), 5.82 (2H,
s), 1.28 ppm (9H, s); [M+H]
+ =294; HRMS C18H19N3O calcd:
294.1601, obsd: 294.1614.
1-(3-(Furan-2-yl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one (66):
1H NMR ([D6]DMSO, 500 MHz): d=8.10 (1H, d, J=8.2 Hz), 7.87 (1H,
d, J=1.7 Hz), 7.52 (1H, d, J=8.5 Hz), 7.56 (2H, m), 7.44 (1H, m),
7.26 (1H, m), 5.72 (2H, s), 1.27 ppm (9H, s); [M+H]
+ =283; HRMS
C17H18N2O2 calcd: 283.1441, obsd: 283.1452.
1-(3-(3-Pyridyl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one (67):
1H NMR ([D6]DMSO, 500 MHz): d=9.17 (1H, m), 8.63 (1H, dd, J=
1.6, 4.8 Hz), 8.35 (1H, dt, J=1.9 7.9 Hz), 8.12 (1H, d, J=8.3 Hz), 7.56
(2H, m), 7.47 (1H, m), 7.29 (1H, m), 5.77 (2H, s), 1.28 ppm (9H, s);
[M+H]
+ =294; HRMS C18H19N3O calcd: 294.1601, obsd: 294.1616.
3,3-Dimethyl-1-(3-(thiophen-3-yl)-1H-indazol-1-yl)butan-2-one
(68):
1H NMR ([D6]DMSO, 500 MHz): d=8.13 (2H, m), 7.69 (2H, m),
7.49 (1H, d, J=8.5 Hz), 7.42 (1H, m), 7.25 (1H, m), 5.70 (2H, s),
1.27 ppm (9H, s); [M+H]
+ =299; HRMS C17H18N2OS calcd:
299.1213, obsd: 299.1219.
1-(3-(1-Isobutyl-1H-pyrazol-4-yl)-1H-indazol-1-yl)-3,3-dimethylbu-
tan-2-one (69):
1H NMR ([D6]DMSO, 500 MHz): d=8.39 (1H, s),
8.04 (1H, d, J=8.1 Hz), 7.99 (1H, s), 7.45 (1H, d, J=8.4 Hz), 7.39
(1H, m), 7.19 (1H, t, J=7.1 Hz), 5.66 (2H, s), 4.01 (2H, d, J=7.2 Hz),
2.20 (1H, m), 1.26 (9H, s), 0.88 ppm (6H, d, J=6.6 Hz); [M+H]
+ =
339; HRMS C20H26N4O calcd: 339.2179, obsd: 339.2183.
1-(3-(3-Chlorophenyl)-1H-indazol-1-yl)-3,3-dimethylbutan-2-one
(70):
1H NMR ([D6]DMSO, 500 MHz): d=8.11 (1H, d, J=8.2 Hz), 7.97
(1H, m), 7.95 (1H, m), 7.56 (2H, m), 7.47 (2H, m), 7.28 (1H, t, J=
7.5 Hz), 5.77 (2H, s), 1.30 ppm (9H, s); [M+H]
+ =327/329; HRMS
C19H19ClN2O calcd: 327.1259, obsd: 327.1262.
Compound 59 was obtained from ChemDiv.
3-(tert-Butylsulfonylmethyl)-1-(3-fluorophenyl)-1H-indazole (73):
To a stirred suspension of indazole-3-carboxylic acid (5 g,
30.8 mmol) in MeOH (125 mL) was added concd H2SO4 (0.5 mL)
and the reaction heated at reflux for 16 h. The reaction mixture
was cooled to room temperature and the solvent removed in va-
cuo. The resultant crude residue was taken up in CH2Cl2, washed
(saturated NaHCO3 solution), dried (MgSO4) and concentrated in
vacuo to give methyl 1H-indazole-3-carboxylate (4.95 g, 91%) as a
white solid; [M+H]
+ =177.
To a stirred solution of methyl 1H-indazole-3-carboxylate (881 mg,
5 mmol) in CH2Cl2 (125 mL), was added 3-fluorophenylboronic acid
(1.40 g, 10 mmol), pyridine (0.81 mL, 10 mmol), copper(II) acetate
(1.36 g, 7.5 mmol) and molecular sieves (4  , 3.82 g) and the reac-
tion stirred (open to air) for 46 h. The reaction mixture was then fil-
tered through a pad of Celite and concentrated in vacuo to give a
crude residue which was purified by column chromatography, elut-
ing with 0–50% Et2O/hexane, to give methyl 1-(3-fluorophenyl)-1H-
indazole-3-carboxylate (332 mg, 25%) as a white solid; [M+H]
+ =
271.
To a stirred solution of methyl 1-(3-fluorophenyl)-1H-indazole-3-car-
boxylate (329 mg, 1.2 mmol) in THF (10 mL) at 08C, under an inert
atmosphere, was added LiAlH4 (185 mg, 4.9 mmol), the reaction
warmed to room temperature and stirred for 16 h. The reaction
mixture was quenched (Na2SO4·10H2O), filtered through a pad of
Celite and concentrated in vacuo. The resultant crude residue was
taken up in 3:1 THF/CH2Cl2 (12 mL), PPh3 (479 mg, 1.826 mmol)
and N-chlorosuccinimide (NCS; 244 mg, 1.8 mmol) added and the
reaction stirred for 24 h. Extra PPh3 (479 mg, 1.8 mmol) and NCS
(244 mg, 1.8 mmol) were then added and stirring continued for
24 h. The reaction mixture was then concentrated in vacuo to give
a crude residue which was taken up in EtOAc, washed (saturated
NaHCO3 solution, H2O, and brine), dried (MgSO4) and concentrated
in vacuo. The resultant crude residue was purified by column chro-
matography, eluting with 0–50% Et2O/hexane, to give 3-(chloro-
methyl)-1-(3-fluorophenyl)-1H-indazole (143 mg, 45%) as a straw-
coloured oil; [M+H]
+ =261/263.
To a stirred solution of 3-(chloromethyl)-1-(3-fluorophenyl)-1H-inda-
zole (46 mg, 0.18 mmol) in CH3CN (3 mL) was added Cs2CO3
(63 mg, 0.19 mmol) and tert-butylthiol (0.022 mL, 0.19 mmol) and
the reaction stirred for 16 h. Extra Cs2CO3 (32 mg, 0.097 mmol) and
tert-butylthiol (0.011 mL, 0.097 mmol) were then added and stirring
continued for 6 h. The reaction mixture was taken up in CH2Cl2,
washed (H2O, brine), dried (MgSO4) and concentrated in vacuo. The
resultant crude residue was purified by column chromatography,
eluting with 0–50% Et2O/hexane, to give 3-(tert-butylthiomethyl)-1-
(3-fluorophenyl)-1H-indazole (45 mg, 81%) as a colourless oil; [M+
H]
+=315.
To a stirred solution of 3-(tert-butylthiomethyl)-1-(3-fluorophenyl)-
1H-indazole (45 mg, 0.14 mmol) in CH2Cl2 (5 mL) was added 70%
mCPBA (141 mg, 0.57 mmol) and the reaction stirred for 2 h.
NaHSO3 solution (2m aq) was added, the layers separated, the or-
ganic layer washed (saturated NaHCO3 solution) and filtered
through a pad of silica, eluting with CH2Cl2 and EtOAc. The filtrate
was concentrated in vacuo to give a crude residue which was puri-
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73 (35 mg, 71%) as a white solid:
1H NMR ([D6]DMSO, 500 MHz):
d=7.97 (1H, dt, J=0.9, 8.1 Hz), 7.95 (1H, dt, J=1.0, 8.5 Hz), 7.67
(3H, m), 7.57 (1H, m), 7.36 (1H, m), 7.30 (1H, m), 5.00 (2H, s),
1.44 ppm (9H, s); [M+H]
+ =347; HRMS C18H19FN2O2S calcd:
347.1224, obsd: 347.1236.
3-(tert-Butylsulfonylmethyl)-1-phenyl-1H-indazole (72): By pro-
ceeding in a similar manner to 3-(tert-butylsulfonylmethyl)-1-(3-flu-
orophenyl)-1H-indazole (see compound 73), except using phenyl-
boronic acid, title compound 72 (35 mg, 81%) was obtained as a
white solid.
1H NMR ([D6]DMSO, 500 MHz): d=7.96 (1H, dt, J=0.9,
8.1 Hz), 7.87 (1H, dt, J=0.9, 8.6 Hz), 7.79 (2H, m), 7.63 (2H, m), 7.54
(1H, m), 7.45 (1H, m), 7.33 (1H, m), 5.00 (2H, s), 1.44 ppm (9H, s);
13C NMR (125 MHz, CDCl3): d=23.9, 48.0, 61.1, 110.5, 121.9, 122.3,
123.0, 124.8, 127.1, 127.7, 129.5, 135.8, 139.7, 140.1 ppm; [M+H]
+
=329; HRMS C18H20N2O2S calcd: 329.1318, obsd: 329.1302.
1-(tert-Butylsulfonylmethyl)-3-(3-fluorophenyl)-1H-indazole (74):
3-(3-Fluorophenyl)-1H-indazole (see compound 71) (0.106 g,
0.5 mmol) was alkylated with tert-butyl(chloromethyl)sulfane
(0.104 g, 0.75 mmol), as in accordance with reported procedures
[28]
to give the intermediate 1-(tert-butylthiomethyl)-3-(3-fluorophenyl)-
1H-indazole (0.055 g, 35%).
1H NMR (CDCl3, 300 K) d=8.03 (1H, dt,
J=7.5 and 0.8 Hz), 7.79 (1H, dt, J=7.7 and 1.2 Hz), 7.71 (1H, ddd,
J=10.0, 2.5 and 1.0 Hz), 7.65 (1H, dt, J=8.5 and 0.8 Hz), 7.51-7.47
(2H, m), 7.29 (1H, m), 7.12 (1H, tdd, J=8.5, 2.5 and 0.8 Hz), 5.68
(2H, s), 1.34 ppm (9H, s); [M+H]
+ =315.
A solution of this sulfide in CH2Cl2 (2 mL) was treated with mCPBA
(Aldrich,  77%; 0.11 g,  0.5 mmol) and stirred at room tempera-
ture for 90 min. The reaction was quenched with 2m aqueous
NaHSO3 (10 mL) and saturated aqueous NaHCO3 (10 mL). The or-
ganic phase was applied to a plug of silica and eluted with CH2Cl2/
EtOAc (0!100%) to give the title compound 74 as a white solid
(0.054 g, 89%):
1H NMR (CDCl3, 300 K): d=8.01 (1H, dt, J=8.2 and
0.9 Hz), 7.78 (1H, dt, J=8.5 and 0.8 Hz), 7.76 (1H, ddd, J=11.7, 1.4
and 1.0 Hz), 7.67 (1H, ddd, J=9.9, 2.5 and 1.5 Hz), 7.55 (1H, ddd,
J=8.4, 7.0 and 1.0 Hz) 7.50 (1H, td, J=8.1 and 5.9 Hz), 7.34 (1H,
ddd, J=8.2, 6.8 and 0.8 Hz), 7.15 (1H, tdd, J=8.4, 2.6 and 0.9 Hz),
5.76 (2H, s), 1.43 ppm (9H, s);
13C NMR (125 MHz, CDCl3): d=23.4,
61.2, 64.6, 110.0, 114.4, 115.5, 121.1, 122.3, 123.2, 127.9, 130.5,
134.8, 142.2, 145.1, 161.2, 164.1 ppm; [M+H]
+ =347; HRMS
C18H19FN2O2S calcd: 347.1224, obsd: 347.1214.
2-(3-(3-Fluorophenyl)-1H-indazol-1-yl)-N-(3-(4-methylpiperazin-1-
yl)propyl)acetamide (80): To a stirred suspension of 60% NaH
(754 mg, 18.9 mmol) in DMF (20 mL) under an inert atmosphere,
was added 3-(3-fluorophenyl)-1H-indazole (1.0 g, 4.7 mmol) in DMF
(10 mL) and the reaction was stirred for 15 min. To the reaction
mixture was added ethyl bromoacetate (2.09 mL, 18.9 mmol), the
reaction was warmed to 758C and stirring continued for 66 h. The
reaction mixture was cooled to room temperature, taken up in
EtOAc, washed (H2O, brine), dried (MgSO4) and concentrated in va-
cuo. The crude residue was taken up in 1:1 THF/H2O (30 mL) and
2m (aq) NaOH (9.43 mL, 18.9 mmol), the reaction was heated at
508C and stirred for 3 h. The reaction was cooled to room temper-
ature, diluted with H2O, extracted (EtOAc), the aqueous layer acidi-
fied (1m (aq) HCl, pH 2), extracted (EtOAc). The organic layer was
dried (MgSO4) and concentrated in vacuo to give 2-(3-(3-fluoro-
phenyl)-1H-indazol-1-yl)acetic acid (980 mg, 77%) as a white foam;
[M+H]
+ =471.
By proceeding in a similar manner to 26, except using 2-(3-(3-fluo-
rophenyl)-1H-indazol-1-yl)acetic acid and 1-(2-aminopropyl)-4-
methylpiperazine, the title compound 80 (65 mg, 43%) was ob-
tained as a white solid:
1H NMR ([D6]DMSO, 500 MHz): d=8.25
(1H, t, J=5.4 Hz), 8.11 (1H, d, J=8.4 Hz), 7.85 (1H, d, J=7.9 Hz),
7.72 (1H, m), 7.68 (1H, d, J=8.9 Hz), 7.58 (1H, m), 7.47 (1H, t, J=
7.7 Hz), 7.27 (2H, m), 5.16 (2H, s), 3.12 (2H, m), 2.51 (8H, m), 2.27
(2H, m), 2.12 (3H, s), 1.58 ppm (2H, m); [M+H]
+ =410; HRMS
C23H28FN5O calcd: 410.2351, obsd: 410.2363.
By proceeding in a similar manner to 26, except using 2-(3-(3-fluo-
rophenyl)-1H-indazol-1-yl)acetic acid and the appropriate amine,
the following compounds were prepared:
N-(3-(1H-Imidazol-1-yl)propyl)-2-(3-(3-fluorophenyl)-1H-indazol-
1-yl)acetamide (81):
1H NMR ([D6]DMSO, 500 MHz): d=8.41 (1H, t,
J=5.4 Hz), 8.25 (1H, s), 8.12 (1H, d, J=8.3 Hz), 7.84 (1H, d, J=
7.9 Hz), 7.72 (2H, m), 7.58 (1H, m), 7.48 (1H, t, J=7.7 Hz), 7.44 (1H,
m), 7.27 (2H, m), 7.23 (1H, m), 5.20 (2H, s), 4.10 (2H, m), 3.09 (2H,
m), 1.93 ppm (2H, m); [M+H]
+ =378; HRMS C21H20FN5O calcd:
378.1725, obsd: 378.1739.
tert-Butyl-4-(2-(2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetami-
do)ethyl)piperazine-1-carboxylate (82):
1H NMR ([D6]DMSO,
500 MHz) d mixture of rotamers d=8.12 (2H, m), 7.86 (1H, d, J=
7.6 Hz), 7.72 (2H, m), 7.59 (1H, m), 7.48 (1H, m), 7.28 (2H, m), 5.22
(2H, s), 3.20 (2H, m), 2.51 (8H, m), 2.37 (2H, m), 1.40(5H, s),
1.39 ppm (4H, s); [M+H]
+ =482; HRMS C26H32FN5O3 calcd:
482.2562, obsd: 482.2570.
N-(2-(Dimethylamino)ethyl)-2-(3-(3-fluorophenyl)-1H-indazol-1-
yl)acetamide (83): NMR
1H NMR ([D6]DMSO, 500 MHz): d=8.22
(1H, t, J=5.5 Hz), 8.12 (1H, d, J=8.2 Hz), 7.85 (1H, d, J=7.9 Hz),
7.72 (1H, m), 7.69 (1H, d, J=8.5 Hz), 7.59 (1H, m), 7.47 (1H, m),
7.26 (2H, m), 5.19 (2H, s), 3.20 (2H, m), 2.31 (2H, m), 2.15 ppm (6H,
s); [M+H]
+ =341; HRMS C19H21FN4O calcd: 341.1772, obsd:
341.1767.
N-(3-(Dimethylamino)propyl)-2-(3-(3-fluorophenyl)-1H-indazol-1-
yl)acetamide (84):
1H NMR ([D6]DMSO, 500 MHz): d=8.26 (1H, t,
J=5.3 Hz), 8.13 (1H, d, J=8.1 Hz), 7.85 (1H, d, J=7.8 Hz), 7.71 (1H,
m), 7.68 (1H, d, J=8.6 Hz), 7.59 (1H, m), 7.48 (1H, m), 7.26 (2H, m),
5.16 (2H, s), 3.13 (2H, m), 2.20 (2H, m), 2.01 (6H, s), 1.54 ppm (2H,
m);
13C NMR (125 MHz, CDCl3): d=24.4, 40.7, 44.5, 52.6, 59.4,
109.5, 114.2, 115.1, 121.2, 122.1, 123.0, 127.3, 130.5, 135.3, 141.7,
144.0, 162.2, 164.2, 167.3 ppm; [M+H]
+ =355; HRMS C20H23FN4O
calcd: 355.1856, obsd: 355.1862.
N-Methyl-(3-(dimethylamino)propyl)-2-(3-(3-fluorophenyl)-1H-in-
dazol-1-yl)acetamide (85):
1H NMR ([D6]DMSO, 500 MHz) mixture
of rotamers; d=8.12 (1H, d, J=8.4 Hz), 7.85 (1H, d, J=7.9 Hz),
7.71 (1H, m), 7.60(2H, m), 7.44 (1H, m), 7.25 (2H, m), 5.60 (1H, s),
5.50 (1H, s), 3.48 (1H, m), 3.30 (1H, m), 3.14 (1.5H, s), 2.84 (1.5H, s),
2.27 (1H, m), 2.20 (3H, s), 2.16 (1H, m), 2.09 (3H, s), 1.77 (1H, m),
1.60 ppm (1H, m); [M+H]
+ =369; HRMS C21H25FN4O calcd:
369.2085, obsd: 369.2097.
N-(4-Chlorobenzyl)-2-(3-(3-fluorophenyl)-1H-indazol-1-yl)aceta-
mide (86):
1H NMR ([D6]DMSO, 500 MHz): d=8.78 (1H, t, J=
5.7 Hz), 8.12 (1H, d, J=8.1 Hz), 7.85 (1H, d, J=7.8 Hz), 7.71 (2H,
m), 7.59 (1H, m), 7.48 (1H, t, J=7.4 Hz), 7.38 (2H, d, J=8.2 Hz),
7.32 (2H, d, J=8.3 Hz), 7.28 (2H, m), 5.26 (2H, s), 4.32 ppm (2H, d,
J=6.0 Hz); [M+H]
+ =394; HRMS C22H17ClFN3O calcd: 394.1117,
obsd: 394.1111.
2-(3-(3-Fluorophenyl)-1H-indazol-1-yl)-N-(2-(4-methylpiperazin-1-
yl)ethyl)acetamide (90):
1H NMR ([D6]DMSO, 500 MHz): d=8.12
(1H, d, J=8.1 Hz), 8.02 (1H, t, J=5.4 Hz), 7.86 (1H, d, J=8.1 Hz),
7.72 (1H, m), 7.71 (1H, d, J=8.6 Hz), 7.59 (1H, m), 7.47 (1H, t, J=
7.8 Hz), 7.27 (2H, m), 5.19 (2H, s), 3.20 (2H, m), 2.51 (8H, m), 2.34
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+ =396; HRMS C22H26FN5O calcd:
396.2194, obsd: 396.2212.
N,N-Diethyl-2-(3-(3-fluorophenyl)-1H-indazol-1-yl)acetamide (87):
3-(3-Fluorophenyl)-1H-indazole (0.106 g, 0.5 mmol), prepared as in
71, was alkylated with 2-chloro-N,N-diethylacetamide (0.102 mL,
0.74 mmol) to give the title compound 87 (0.073 g, 45%) as a
white solid:
1H NMR (CDCl3, 300 K): d=8.02 (1H, d, J=8.2 Hz), 7.78
(1H, d, J=7.8 Hz), 7.70 (1H, ddd, J=10.1 2.2 and 1.5 Hz), 7.53 (1H,
d, J=8.5 Hz), 7.50-7.45 (2H, m), 7.27 (1H, m), 7.11 (1H, td, J=7.5
and 2.0 Hz), 5.30 (2H, s), 3.54 (2H, q, J=7.1 Hz), 3.43 (2H, q, J=
7.1 Hz), 1.17 ppm (6H, m); [M+H]
+ =326; HRMS C19H20FN3O calcd:
326.1663, obsd: 326.1663.
2-(3-(3-Fluorophenyl)-1H-indazol-1-yl)-N,N-dimethylacetamide
(88): 3-(3-Fluorophenyl)-1H-indazole (0.106 g, 0.5 mmol), prepared
as in 71, was alkylated with 2-chloro-N,N-dimethylacetamide
(0.191 g, 1.6 mmol) to give the title compound 88 (0.114 g, 77%)
as a white solid.
1H NMR (CDCl3, 300 K): d=1H, d, J=8.2 Hz), 7.78
(1H, d, J=7.7 Hz), 7.70 (1H, ddd, J=10.1, 2.4 and 1.6 Hz), 7.52-7.45
(3H, m), 7.27 (1H, m), 7.10 (1H, ddt, J=8.5, 2.6 and 0.8 Hz), 5.32
(2H, s), 3.18 (3H, s), 3.01 ppm (3H, s); [M+H]
+=298; HRMS
C17H16FN3O calcd: 298.1350, obsd: 298.1348.
2-(3-(3-Fluorophenyl)-1H-indazol-1-yl)-1-(piperidin-1-yl)ethanone
(89): Synthesis previously described.
[20] 3-(3-Fluorophenyl)-1H-inda-
zole (0.106 g, 0.50 mmol), prepared as in 71, was alkylated with 2-
chloro-1-piperidin-1-ylethanone (0.350 g, 2.2 mmol) to give the
title compound (0.05 g, 30%) as a white solid:
1H NMR (CDCl3,
300 K): d=8.03 (1H, d, J=8.2 Hz), 7.77 (1H, d, J=7.8 Hz), 7.69 (1H,
dt, J=10.0 and 1.7 Hz), 7.55 (1H, d, J=8.5 Hz), 7.50-7.45 (2H, m),
7.27 (1H, m), 7.11 (1H, td, J=8.4 and 1.4 Hz), 5.32 (2H, s), 3.60 (4H,
m), 1.64 (2H, m), 1.54 (2H, m), 1.48 ppm (2H, m); [M+H]
+ =338;
HRMS C20H20FN3O calcd: 338.1663, obsd: 338.1660.
Biological assays
Trypanothione synthetase assay: The TryS enzyme assays were con-
ducted as reported.
[20]
Cell-based assays: Proliferation assays using bloodstream form
T. brucei and human MRC5 fibroblasts were conducted as report-
ed.
[17]
Abbreviations
Glutathione (GSH); human African trypanosomiasis (HAT); spermi-
dine (Spd); single knockout (SKO); Trypanothione synthetase (TryS).
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